#BEGIN_DRUGCARD DB07231

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C22H29N3O6

# Chemical_IUPAC_Name:
(2S)-1-[(2S,3S)-2-{[(2S,3S)-3-(benzylcarbamoyl)oxiran-2-yl]formamido}-3-methylpentanoyl]pyrrolidine-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:19:45 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE

# HET_ID:
78A

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C22H29N3O6/c1-3-13(2)16(21(28)25-11-7-10-15(25)22(29)30)24-20(27)18-17(31-18)19(26)23-12-14-8-5-4-6-9-14/h4-6,8-9,13,15-18H,3,7,10-12H2,1-2H3,(H,23,26)(H,24,27)(H,29,30)/t13-,15-,16-,17-,18-/m0/s1

# InChI_Key:
InChIKey=MERYMLLGRCNRKE-HILJTLORSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
7237

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
431.4822

# Molecular_Weight_Mono:
431.205635675

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.31

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
4.84e-01 g/l

# Primary_Accession_No:
DB07231

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
23647361

# PubChem_Substance_ID:
99443702

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCC1=CC=CC=C1)C(=O)N1CCC[C@@]1([H])C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:25:23 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CTSB

# Drug_Target_1_GenBank_ID_Gene:
M14221

# Drug_Target_1_GenBank_ID_Protein:
181192

# Drug_Target_1_GeneCard_ID:
CTSB

# Drug_Target_1_Gene_Name:
CTSB

# Drug_Target_1_Gene_Sequence:
>1020 bp
ATGTGGCAGCTCTGGGCCTCCCTCTGCTGCCTGCTGGTGTTGGCCAATGCCCGGAGCAGG
CCCTCTTTCCATCCCGTGTCGGATGAGCTGGTCAACTATGTCAACAAACGGAATACCACG
TGGCAGGCCGGGCACAACTTCTACAACGTGGACATGAGCTACTTGAAGAGGCTATGTGGT
ACCTTCCTGGGTGGGCCCAAGCCACCCCAGAGAGTTATGTTTACCGAGGACCTGAAGCTG
CCTGCAAGCTTCGATGCACGGGAACAATGGCCACAGTGTCCCACCATCAAAGAGATCAGA
GACCAGGGCTCCTGTGGCTCCTGCTGGGCCTTCGGGGCTGTGGAAGCCATCTCTGACCGC
ATCTGCATCCACACCAATGCGCACGTCAGCGTGGAGGTGTCGGCGGAGGACCTGCTCACC
TGCTGTGGCAGCATGTGTGGGGACGGCTGTAATGGTGGCTATCCTGCTGAAGCTTGGAAC
TTCTGGACAAGAAAAGGCCTGGTTTCTGGTGGCCTCTATGAATCCCATGTAGGGTGCAGA
CCGTACTCCATCCCTCCCTGTGAGCACCACGTCAACGGCTCCCGGCCCCCATGCACGGGG
GAGGGAGATACCCCCAAGTGTAGCAAGATCTGTGAGCCTGGCTACAGCCCGACCTACAAA
CAGGACAAGCACTACGGATACAATTCCTACAGCGTCTCCAATAGCGAGAAGGACATCATG
GCCGAGATCTACAAAAACGGCCCCGTGGAGGGAGCTTTCTCTGTGTATTCGGACTTCCTG
CTCTACAAGTCAGGAGTGTACCAACACGTCACCGGAGAGATGATGGGTGGCCATGCCATC
CGCATCCTGGGCTGGGGAGTGGAGAATGGCACACCCTACTGGCTGGTTGCCAACTCCTGG
AACACTGACTGGGGTGACAATGGCTTCTTTAAAATACTCAGAGGACAGGATCACTGCGGA
ATCGAATCAGAAGTGGTGGCTGGAATTCCACGCACCGATCAGTACTGGGAAAAGATCTAA

# Drug_Target_1_General_Function:
Involved in cysteine-type endopeptidase activity

# Drug_Target_1_General_References:
1637335	Moin K, Day NA, Sameni M, Hasnain S, Hirama T, Sloane BF: Human tumour cathepsin B. Comparison with normal liver cathepsin B. Biochem J. 1992 Jul 15;285 ( Pt 2):427-34.
1868826	Musil D, Zucic D, Turk D, Engh RA, Mayr I, Huber R, Popovic T, Turk V, Towatari T, Katunuma N, et al.: The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 1991 Sep;10(9):2321-30.
3010323	Fong D, Calhoun DH, Hsieh WT, Lee B, Wells RD: Isolation of a cDNA clone for the human lysosomal proteinase cathepsin B. Proc Natl Acad Sci U S A. 1986 May;83(9):2909-13.
3463996	Chan SJ, San Segundo B, McCormick MB, Steiner DF: Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7721-5.
3972105	Ritonja A, Popovic T, Turk V, Wiedenmann K, Machleidt W: Amino acid sequence of human liver cathepsin B. FEBS Lett. 1985 Feb 11;181(1):169-72.
8112600	Cao L, Taggart RT, Berquin IM, Moin K, Fong D, Sloane BF: Human gastric adenocarcinoma cathepsin B: isolation and sequencing of full-length cDNAs and polymorphisms of the gene. Gene. 1994 Feb 25;139(2):163-9.
8617355	Turk D, Podobnik M, Kuhelj R, Dolinar M, Turk V: Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS Lett. 1996 Apr 22;384(3):211-4.
9299326	Podobnik M, Kuhelj R, Turk V, Turk D: Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. J Mol Biol. 1997 Sep 5;271(5):774-88.

# Drug_Target_1_HGNC_ID:
HGNC:2527

# Drug_Target_1_HPRD_ID:
00287

# Drug_Target_1_ID:
1233

# Drug_Target_1_Locus:
8p22

# Drug_Target_1_Molecular_Weight:
37822

# Drug_Target_1_Name:
Cathepsin B

# Drug_Target_1_Number_of_Residues:
339

# Drug_Target_1_PDB_ID:
3PBH

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00112	Peptidase_C1
PF08127	Propeptide_C1

# Drug_Target_1_Protein_Sequence:
>Cathepsin B precursor
MWQLWASLCCLLVLANARSRPSFHPLSDELVNYVNKRNTTWQAGHNFYNVDMSYLKRLCG
TFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQGSCGSCWAFGAVEAISDR
ICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGGYPAEAWNFWTRKGLVSGGLYESHVGCR
PYSIPPCEHHVNGSRPPCTGEGDTPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIM
AEIYKNGPVEGAFSVYSDFLLYKSGVYQHVTGEMMGGHAIRILGWGVENGTPYWLVANSW
NTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI

# Drug_Target_1_Reaction:
Hydrolysis of proteins with broad specificity for peptide bonds. Preferentially cleaves -Arg-Arg! bonds in small molecule substrates (thus differing from cathepsin L). In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides

# Drug_Target_1_Signals:
1-17

# Drug_Target_1_Specific_Function:
Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis

# Drug_Target_1_SwissProt_ID:
P07858

# Drug_Target_1_SwissProt_Name:
CATB_HUMAN

# Drug_Target_1_Synonyms:
APP secretase
APPS
Cathepsin B precursor
Cathepsin B1
EC 3.4.22.1

# Drug_Target_1_Theoretical_pI:
6.27

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB07231
